4ZDI

Crystal structure of the M. tuberculosis CTP synthase PyrG (apo form)


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.52 Å
  • R-Value Free: 0.221 
  • R-Value Work: 0.213 
  • R-Value Observed: 0.213 

wwPDB Validation   3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrG.

Mori, G.Chiarelli, L.R.Esposito, M.Makarov, V.Bellinzoni, M.Hartkoorn, R.C.Degiacomi, G.Boldrin, F.Ekins, S.de Jesus Lopes Ribeiro, A.L.Marino, L.B.Centarova, I.Svetlikova, Z.Blasko, J.Kazakova, E.Lepioshkin, A.Barilone, N.Zanoni, G.Porta, A.Fondi, M.Fani, R.Baulard, A.R.Mikusova, K.Alzari, P.M.Manganelli, R.de Carvalho, L.P.Riccardi, G.Cole, S.T.Pasca, M.R.

(2015) Chem Biol 22: 917-927

  • DOI: 10.1016/j.chembiol.2015.05.016
  • Primary Citation of Related Structures:  
    4ZDI, 4ZDJ, 4ZDK

  • PubMed Abstract: 
  • To combat the emergence of drug-resistant strains of Mycobacterium tuberculosis, new antitubercular agents and novel drug targets are needed. Phenotypic screening of a library of 594 hit compounds uncovered two leads that were active against M. tuberculosis in its replicating, non-replicating, and intracellular states: compounds 7947882 (5-methyl-N-(4-nitrophenyl)thiophene-2-carboxamide) and 7904688 (3-phenyl-N-[(4-piperidin-1-ylphenyl)carbamothioyl]propanamide) ...

    To combat the emergence of drug-resistant strains of Mycobacterium tuberculosis, new antitubercular agents and novel drug targets are needed. Phenotypic screening of a library of 594 hit compounds uncovered two leads that were active against M. tuberculosis in its replicating, non-replicating, and intracellular states: compounds 7947882 (5-methyl-N-(4-nitrophenyl)thiophene-2-carboxamide) and 7904688 (3-phenyl-N-[(4-piperidin-1-ylphenyl)carbamothioyl]propanamide). Mutants resistant to both compounds harbored mutations in ethA (rv3854c), the gene encoding the monooxygenase EthA, and/or in pyrG (rv1699) coding for the CTP synthetase, PyrG. Biochemical investigations demonstrated that EthA is responsible for the activation of the compounds, and by mass spectrometry we identified the active metabolite of 7947882, which directly inhibits PyrG activity. Metabolomic studies revealed that pharmacological inhibition of PyrG strongly perturbs DNA and RNA biosynthesis, and other metabolic processes requiring nucleotides. Finally, the crystal structure of PyrG was solved, paving the way for rational drug design with this newly validated drug target.


    Organizational Affiliation

    Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy. Electronic address: mariarosalia.pasca@unipv.it.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
CTP synthaseA, B, C, D, E, F, G, H587Mycobacterium tuberculosis H37RvMutation(s): 0 
Gene Names: pyrGRv1699MTCI125.21
EC: 6.3.4.2
UniProt
Find proteins for P9WHK7 (Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv))
Explore P9WHK7 
Go to UniProtKB:  P9WHK7
Protein Feature View
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.52 Å
  • R-Value Free: 0.221 
  • R-Value Work: 0.213 
  • R-Value Observed: 0.213 
  • Space Group: P 43
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 196.826α = 90
b = 196.826β = 90
c = 184.047γ = 90
Software Package:
Software NamePurpose
BUSTERrefinement
XDSdata reduction
XSCALEdata scaling
PHASERphasing

Structure Validation

View Full Validation Report




Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
European CommissionFranceHEALTH-F3-2011-260872

Revision History  (Full details and data files)

  • Version 1.0: 2015-07-01
    Type: Initial release
  • Version 1.1: 2015-08-05
    Changes: Database references